-
101
Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?
Published 2025“…Mean HbA1c significantly decreased from 8.1%preop to 6.77%<sub>year 9</sub>. …”
-
102
Investigating the Impact of Salinity Variations on Aerobic Granules and Activated Sludge Flocs: Emphasis on Performance Monitoring and Identification of Influential Salinity Compon...
Published 2022“…Cell viability remained unaffected for the reactors operating under single salt solutions of NaCl, while there was a significant reduction in live viabilities following the change to KCl and Na<sub>2</sub>SO<sub>4</sub> solutions to ~ 50%. …”
-
103
-
104
Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in...
Published 2022“…The primary outcome of the study was the change in the time spent in the target in range (TIR) of 70–180 mg/dl and HbA1c from baseline (MDI + CGM, 1 week) to study phase (AHCL, 12 weeks). …”
-
105
Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS
Published 2018“…The glucose disposal rate during the lipid infusion was reduced following exercise in PCOS, indicating decreased IR (67 ± 5 vs. 50 ± 7%, p = 0.02), but IR was not altered in controls (49 ± 7 vs. 45 ± 6%, p = 0.58). …”
-
106
-
107
-
108
-
109
-
110
Understanding the Molecular Mechanisms of Dysglycemia in Patients with Fanconi-Bickel Syndrome
Published 2023“…Our results showed that two patients had exonic <i>SLC2A2</i> mutations [db-bl-1164 (c.901C>T, R301X) and db-bl-1538 (c.1093C > T, R365X)]; and one patient had an intronic <i>SLC2A2</i> mutation [db-bl-0008 (c.613-7T>G)]. …”
-
111
-
112
Preterm birth in low-middle income Countries
Published 2024Get full text
Get full text
Get full text
article -
113
-
114
-
115
-
116
Exploring Beyond Numeric Weight Loss: The Metabolic Effects of Semaglutide.
Published 2025“…Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7%, 0.5mg dose lowered HbA1c by 1.2–1.5%, while the 1.0 mg dose reduced it by 1.4–1.8%. …”
Get full text
Get full text
Get full text
article -
117
-
118
-
119
-
120
Exploring beyond numeric weight loss: The metabolic effects of semaglutide
Published 2025“…Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7 %, 0.5 mg dose lowered HbA1c by 1.2–1.5 %, while the 1.0 mg dose reduced it by 1.4–1.8 %. …”